Pheochromocytoma/paraganglioma (PPGL)-induced catecholamine crisis is a rare endocrine emergency leading to life-threatening hemodynamic instability causing end-organ damage or dysfunction. As it is associated with a significant mortality rate of approximately 15%, recognizing the signs and symptoms and making the appropriate diagnosis are critical. For this purpose, we report the clinical course of the crisis in four out of a total of six patients with a PPGL crisis from a cohort of 199 PPGL patients of a single tertiary referral center for PPGL patients in the Netherlands diagnosed between 2002 and 2020. Successful treatment of a PPGL crisis demands prompt diagnosis, vigorous pharmacological therapy, and emergency tumor removal if the patient continues to deteriorate.
14 March 2021 in Journal of Endocrinological Investigation
Introduction: In addition to catecholamines, pheochromocytomas and paragangliomas (PPGL) may secrete interleukin-6 (IL-6). IL-6 contributes to the development of unusual symptoms, which may hinder the diagnosis. Patients and methods: We report the clinical course and subsequent treatment of IL-6 producing PPGL in three patients from a single tertiary referral centre for PPGL patients in the Netherlands. Conclusion: PPGL combined with persistent elevated inflammatory markers, either in the presence or absence of pyrexia, raised suspicion of IL-6 overproduction in these three patients. Although surgical resection of the tumour is the only curative treatment option, our case series adds to the accumulating evidence that alpha-blockers might be effective in these patients.
Low-dose interleukin-2 (IL-2) shows potential for treating autoimmune disorders by expanding regulatory T cells (Treg), but therapeutic utility is limited by short half-life and off-target effects. Here, we describe the molecular design, nonclinical development, and first-in-human study of MHS552, an IL-2 mutein-engrafted antibody designed to selectively expand Treg via high-affinity IL-2 receptors. In vitro, MHS552 selectively induces IL-2 signaling in Treg from healthy donors and autoimmune patients. In cynomolgus monkeys, MHS552 produces dose-dependent Treg expansion, with modest increases in conventional T cells (Tconv) at higher doses. In a randomized, double-blind, placebo-controlled, single-ascending-dose trial in 60 healthy participants (EudraCT 2018-004233-33), evaluating safety and tolerability as the primary objective and pharmacokinetics as the secondary objective, intravenous and subcutaneous administration of MHS552 is well tolerated at lower doses and shows a predictable pharmacokinetic profile. However, a serious adverse event (SAE) is reported at the highest subcutaneous dose. Both administration routes result in dose-dependent Treg expansion, with up to 6-fold increase in total Treg and 60-fold increase in CD25hi subset, without significant conventional T cell activation. Exploratory analyses confirm selective Treg activation, with expanded Treg retaining their suppressive function ex vivo. These findings support IL-2-based therapeutics for autoimmune disorders, while the SAE highlights the need for careful safety evaluation.
No disease-modifying drugs are approved for osteoarthritis (OA), a prevalent and debilitating chronic condition. Based on preclinical data, LRX712 was envi
12 September 2025 in British Journal of Clinical Pharmacology
Problem Setting: As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS).Solution: At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while still gaining valuable insights into the mode of action of the investigational medicinal product (IMP). Systematic evaluation of AIS is crucial to better understand the underlying pathophysiological mechanism. This can be achieved using standardized blood sampling to measure specific AIS biomarkers. The results of these analyses can be used to decide whether mitigation measures are needed, such as potential IMP re‐exposure and the use of pre‐medication. Additionally, systematic evaluation of AIS biomarkers throughout early phase clinical trials contributes to a better understanding of the IMP‐specific mechanism of action. This supports more informed decision making as the development progresses. Ultimately, it can lead to more efficient and informative clinical trials and may prevent unnecessary discontinuation of promising drugs.
12 June 2026 in British Journal of Clinical Pharmacology
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis. To bridge this translational gap, we compare here the experimental conduct, readouts and mechanistic insights engaged by IMQ challenge in mice vs . healthy human participants. Importantly, molecular and cellular analyses indicate that IMQ predominantly activates interferon regulatory factor (IRF) signalling in humans, rather than NF‐κB pathways as observed in animals. Moreover, differences in neutrophil response and complement activation were also identified. These discrepancies may reflect interspecies variation in TLR7 expression as well as methodological differences between the animal and human IMQ model. Despite certain limitations related to psoriasis translatability, the human IMQ model has demonstrated translational relevance in several early phase clinical trials. It represents a valuable tool for evaluating target engagement and characterizing downstream pharmacodynamic effects of novel compounds, particularly those targeting the TLR7–IRF‐type I interferon axis. In conclusion, the human IMQ model can serve as valuable mechanistic model driving disease‐related pathways, rather than as a proxy for plaque psoriasis disease biology. Fit‐for‐purpose benchmarking and method standardization are essential to maximize translational utility of the IMQ model.